The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Dainippon Sumitomo Pharma; Eisai; Lilly Japan; Nobelpharma; Novartis; Otsuka; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; NanoCarrier; Novartis; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxalta/Shire; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; NanoCarrier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takara Bio; Yakult Pharmaceutical
 
Makoto Ueno
Honoraria - AstraZeneca; Lilly; Novartis; Ono Pharmaceutical; Shire; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Shire
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Shire (Inst); Taiho Pharmaceutical (Inst)
 
Chigusa Morizane
Honoraria - Fujifilm; Lilly; Nobelpharma; Novartis; Pfizer; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Eisai (Inst); Nobelpharma (Inst); ONO PHARMACEUTICAL (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Satoshi Kobayashi
Honoraria - AstraZeneca; Bayer Yakuhin; Boston Scientific; Daiichi Sankyo; Kyowa Hakko Kirin; Merck Serono; Nippon Kayaku; Taiho Pharmaceutical
Speakers' Bureau - Kyowa Hakko Kirin
Research Funding - Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Izumi Ohno
Consulting or Advisory Role - Merck Serono
Speakers' Bureau - Taiho Pharmaceutical
 
Shunsuke Kondo
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst)
 
Naohiro Okano
Honoraria - Merck Serono; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Keisuke Kimura
Employment - Ono Pharmaceutical
 
Suguru Asada
Employment - Ono Pharmaceutical
 
Yoshinobu Namba
Employment - Ono Pharmaceutical
 
Takuji Okusaka
Honoraria - Abbvie; AstraZeneca Japan; Bayer Yakuhin; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Fujifilm; Lilly; Nobelpharma; Novartis; Ono Pharmaceutical; Pfizer; Shire; Taiho Pharmaceutical; Takara Bio; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Dainippon Sumitomo Pharma; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - Eisai; Lilly; Novartis; Taiho Pharmaceutical; Yakult Honsha
 
Junji Furuse
Honoraria - Astellas Pharma; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)